FDA, Big Pharma Act Quickly to Control Counterfeiting Upsurge
Drug counterfeiting is on the rise--and drugs with inactive, incorrect, subpotent or superpotent ingredients are entering into the US drug supply at alarming rates. FDA commissioner Mark McClellan, MD, PhD has made it clear that identifying the best means to keep the drug supply safe is a fast-track effort at the agency. And this is not merely a top-priority regulatory effort--Big Pharma firms, fearful of safety problems--and, although they don't say so, lost sales--have lots of incentive to get involved in looking for solutions, too.
You may also be interested in...
It's technically illegal for US citizens to buy pharmaceuticals from Canada, but that's not stopping anybody. Indeed, the trend is gaining momentum at the state level. Pharmaceutical and biotech companies have a range of options for responding to re-importation, such as emphasizing the safety risks of new purchasing channels, limiting shipments into Canada, and getting tougher in price negotiations. Making pricing a trade issue might help the industry, but it's a tough case to argue. If worse comes to worst, companies may need to take legal recourse. If re-importation continues unchallenged, it is likely to lead to US price controls.
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.